ArticleThe Laryngoscope2026
Prospective Study of Long-Term Outcomes and the Patient Experience With Superior Laryngeal Nerve Block for Chronic Cough.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnosis and Treatment of Refractory Chronic Cough: An American Broncho-Esophagological Association Expert Consensus Statement.The Laryngoscope · 2026Article
- Prospective Study of Long-Term Outcomes and the Patient Experience With Superior Laryngeal Nerve Block for Chronic Cough.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize long-term response rates to the superior laryngeal nerve (SLN) block in a prospective fashion. Secondary objectives are to provide objective data to answer common pre-procedural questions and to identify factors that predict injection outcomes.
methodsProspective study from April 2021 to August 2024 of adult patients with refractory chronic cough undergoing SLN block. Response was measured via a yes/no question about improvement, cough severity index (CSI), and a 1-10 Likert scale grading cough impact on quality of life (QoL) taken at baseline, 2 weeks, and 6-9 months post-injection.
resultsOne hundredtwenty-two patients were injected for cough, representing 249 injections. At 2 weeks after injection, 63.1% endorsed improvement on yes/no questioning ("initial improvers"), with significant improvement in both CSI and QoL scores (p < 0.001 for each). Of the initial improvers, 53.2% reported ongoing symptom improvement at long-term follow-up (6-9 months). Improvement occurred at an average of 4.3 days after injection and averaged 4.1 months in duration. 72.1% of improvers reported their degree of improvement as "a lot" or "completely." Side effects occurred in 44.2% of injections and were typically mild. No cough feature or clinical factor significantly predicted a positive response to the SLN block.
conclusionThis prospective assessment indicates that nearly 2 in 3 refractory chronic cough patients respond positively to SLN block, with ~50% of these initial improvers endorsing ongoing improvement at long-term follow-up. Average duration of benefit is 4 months, and side effects are common. Predictive factors of a positive response to SLN block remain undefined. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.